







SABITHA KESAVAN1*, PRIYA RAMANATHAN1, RAJKUMAR THANGARAJAN1 
1
 Received: 07 May 2015 Revised and Accepted: 08 Aug 2015 
Department of Molecular Oncology, Cancer Institute (WIA) 38, Sardar Patel Road, Guindy, Chennai 600036, Tamil Nadu, India 
Email: rk.sabitha@gmail.com    
ABSTRACT 
Objective: We have made an attempt to identify inhibitors that are bound with Acrosin binding protein (ACRBP/OY-TES-1) through In silico 
molecular docking studies. 
Methods: Modeling of ACRBP/OY-TES-1 was performed using Iterative Threading Assembly Refinement (I-TASSER) software. Docking calculations 
were carried out using Glide. Glide Score (GS core) was used to rank the ligands on the basis of their relative binding affinities. 
Results: Food and Drug Administration (FDA)-approved drugs were docked with ACRBP/OY-TES-1 to identify potent inhibitors. Leuprolide a 
decapeptide interacts with the protein at residues Tyr116, Gly421, Leu433, Asp480 and Gln483 with Glide score-14.188. Other compounds that 
showed high affinity to the protein are triptorelin, nafatarelin, goserelin and sincalide. 
Conclusion: The investigation concluded that these drugs could be used as potential inhibitors against ACRBP/OY-TES-1 in cancer treatment. 
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INTRODUCTION  
Cancer remains a fundamental burden to public health despite 
substantial efforts aimed at developing effective chemotherapeutics 
and significant advances in chemotherapeutic regimen. The major 
challenge in anti-cancer drug design is to selectively target cancer 
cells with high specificity [1]. Target-based therapies are widely 
considered to be the future of cancer treatment and much attention 
has been focused on developing inhibitors of the target proteins [2]. 
Hence the identification of target proteins and the understanding of 
their interaction with ligands are key elements of modern 
biomedical research [3]. The interaction with target proteins is the 
molecular origin of most drugs, their particular importance for 
molecular biology, molecular pharmacy and pharmaceutical sciences 
is obvious [4, 5]. Many small-molecule identification or drug 
discovery efforts start by selecting a target that is expected to 
modulate a pathway or disease of interest [6]. Different types of 
proteins are involved in different types of cancers which are 
sensitive to small molecules. The anticancer drugs that are currently 
available for the treatment of cancer are not specific. The major 
cause of limited success of chemotherapy is an acquisition of drug 
resistance by tumors, inadequate target drug delivery due to 
abnormal tumor vasculature, and its toxicity [7, 8]. Hence there is a 
need to identify a novel protein molecule as a target for 
development of therapeutic agents. 
One such protein Acrosin binding protein (ACRBP) or OY-TES-1 is 
expressed in normal testis and over expressed in many cancers such 
as melanoma, breast cancer, bladder cancer, prostate cancer, 
esophageal squamous cell carcinoma and hepatocellular carcinoma 
[9]. Acrosin binding protein or cancer/testis antigen/OY-TES-1 is a 
61359 Da protein consists of two domains-Proacrosin binding sp32 
(1–240) and the kazal domain (469–509). ACRBP/OY-TES-1 maps to 
chromosome 12p12-p13 and contains 10 exons [9]. This protein is 
located in the sperm acrosome and is thought to function as a 
binding protein to proacrosin for packaging and condensation of the 
acrosin zymogen in the acrosomal matrix. This protein is a member 
of the cancer/testis (CT) family of antigens and it is found to be 
immunogenic [10]. Luo et al.’s finding demonstrates that 
ACRBP/OY-TES-1 is frequently expressed in colorectal cancer (CRC) 
and can induce humoral immune response spontaneously in CRC 
patients, suggesting that it might be a promising immunotherapy 
target for CRC [11]. In ovarian cancer high ACRBP/OY-TES-1 
expression is significantly correlated with poor prognosis, both with 
respect to overall survival and time to disease recurrence [12]. 
Studies showed that ACRBP/OY-TES-1 supports mitotic spindle 
fidelity in tumor cells by regulating NUMA1 protein levels and 
thereby reinforcing bipolar spindle assembly in the presence of 
paclitaxel [12]. NuMA over expression was suggested to cause 
mitotic perturbations required for the plasticity of the preneoplastic 
genome, with co-evolving over expression of ACRBP as tumors 
progress [13]. Fig. 1 provides an overview of ACRBP’s role in 
promoting cancer cell proliferation. 
 
 
Fig. 1: Role of ACRBP/OY-TES-1 in tumors 
 
Given the extensive expression correlation with cancer and 
restricted expression pattern in normal tissues, we thought to model 
the protein ACRBP/OY-TES-1 by computational methods and 
perform docking studies to identify a novel compound.  
Drug discovery is a lengthy and most expensive step with high 
failure rates. Whereas approved drugs have acceptable 
pharmacokinetics, safety profiles and are accepted by regulatory 
agencies for human use, and it is important to address whether it is 
International Journal of Pharmacy and Pharmaceutical Sciences 
ISSN- 0975-1491                  Vol 7, Issue 9, 2015 
Innovare 
Academic Sciences 
Kesavan et al. 
Int J Pharm Pharm Sci, Vol 7, Issue 9, 491-495 
 
492 
preferable to use them as a whole or as a template for further design 
of new molecules [14]. So, we took FDA approved drugs for docking 
studies to avoid false-positive predictions and to design new drugs 
with high accuracy and selectivity.  
In a protein targeting drug discovery, 3D structure of the protein 
should be known. Crystal structure of ACRBP/OY-TES-1 is not 
available in the protein data bank. So, this study aims to model the 
protein and identify the binding sites computationally. Docking 
studies were carried out to design, optimize and identify potential 
inhibitors for ACRBP/OY-TES-1. 
MATERIALS AND METHODS 
Protein modeling  
The Amino acid sequence of ACRBP/OY-TES-1 was obtained from 
Uniprot Acc NO: Q8NEB7. Modeling of ACRBP/OY-TES-1 was 
performed using I-TASSER software. I-TASSER is a hierarchical 
protein structure modeling approach based on the secondary-
structure enhanced Profile-Profile threading Alignment (PPA) [15, 
16] and the iterative implementation of the Threading ASSEmbly 
Refinement (TASSER) program [17]. The I-TASSER method has been 
described in detail previously [18, 19]. Maestro 9.8 protein 
preparation wizard (Schrodinger) was used to correct errors in the 
modeled structure. 
Active site identification 
Site Map, Schrödinger’s program was used for identifying, evaluating, 
and visualizing ligand binding sites. A receptor grid was generated 
around the active site and was given a dimension sufficient to 
accommodate compounds with a length ≤15A˚. The ligand-midpoint 
box was given a side of 10A˚. No scaling factors were applied to the van 
der Waals (vdW) radii of the receptor atoms [20]. 
Ligand preparation 
The FDA approved drugs were downloaded from e-LEA3D: Chem 
Informatic Tools and Databases (http://chemoinfo.ipmc.cnrs.fr/ 
download.html). Ligands were subjected to automatic preparation 
process, performed with Lig Prep (LigPrep, version 3.2, Schrödinger, 
LLC, New York, NY, 2014.) tool of the Schrodinger package. It 
generates all possible protonation and tautomeric states available 
within a pH range of 7.0±2.0.  
Molecular docking  
Docking calculations were carried out using Glide (Glide, version 6.5, 
Schrödinger, LLC, New York, NY, 2014). The prepared and optimized 
ligands were flexibly docked in the grid box of the protein using 
MCSA (Monte Carlo based simulated algorithm) based minimization 
[21, 22]. Glide Score (GScore) was used to rank the ligands on the 
basis of their relative binding affinities. 
RESULTS 
A phylogenetic analysis was done to determine ACRBP/OY-TES-1 
evolutionary history between different species [23]. Evolutionary 
relationships can determine how many species are closely related or 
deviated from Humans. Neighbor joining tree for ACRBP/OY-TES-1 
is shown in fig. 2. The phylogenetic analysis reveals that there are 51 
speciation nodes of ACRBP/OY-TES-1 with one duplication event. 
The human gene was orthologous to Chimpanzees and also showed 
a close relationship with gorillas, Orangutans and Gibbons. The 
sequence similarities between these species are around 60%. Other 
species such as rodents, birds and amphibians are paralogs of 
humans. The tree shows the evolutionary descent of the ancestral 




Fig. 2: Gene tree for the ACRBP/OY-TES-1 Gene 
 
The protein sequence of ACRBP/OY-TES-1 consists of 543 amino 
acids. Protparam analysis revealed the presence of 72 negatively 
charged and 48 positively charged residues. The molecular weight 
was found to be 49161.6 Daltons and theoretical isoelectric point 
was 5.09 [24]. The secondary structure of ACRBP/OY-TES-1 was 
predicted by the Chou and Fasman Secondary Structure Prediction 
Server. It was noticed that ACRBP/OY-TES-1 consists of Helix 61.9%, 
extended strand 68.3% and turn 13.1% [25]. The functional domain 
predictions with SMART tool predicted 3 low complexity regions 
from 9–25, 177-191, 209–243. It shows two domains (PBP_sp32 
domain & Kazal Domain). The PBP_sp32 domain shared similarity 
with Pfam database. This family consists of several mammalian 
specific proacrosin binding protein sp32 sequences. sp 32 is a sperm 
specific protein, which is known to bind with 53 kDa proacrosins 
and the 49 kDa acrosin intermediate. This domain starts at position 
1 and ends at position 240 with e value of 3.1 e-138. The kazal 
domain is starting from 469 and ends at position 509. It is kazal type 
proteinase inhibitors and is distributed in a wide range of organisms 
from all kingdoms of life and plays a crucial role in various 
physiological mechanisms [26] (fig. 3). 
 
 
Fig. 3: Domain architecture of ACRBP/OY-TES-1 
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The protein data bank (PDB) was checked for the 3D structure of the 
selected protein, and it was confirmed that no 3D structure had been 
predicted to date. Therefore, we decided to predict the three-
dimensional (3D) model of the ACRBP/OY-TES-1 protein by using 
homology modeling, threading and ab-initio methods. As low of 
percentage of sequence identity, not more than 25%, we modeled 
the protein with ab-initio method by using I-TASSER simulations, 
where 5 predicted models were obtained. The modeled structure 
was imported into protein preparation wizard to correct its bond 
orders and atomic charges. Hydrogen atoms were added, bond orders 
were assigned to certain amino acid residues and tautomeric states at 
pH 7.0 were generated. Protonation states of hydroxyl, histidine 
groups and side chain atoms of the protein were optimized (fig. 4).  
 
 
Fig. 4: Ribbon view of ACRBP/OY-TES-1 
 
Impref minimization was carried out using the OPLS 2005 constant 
dielectric force field. The final minimized model was used to identify 
active binding pockets and for further docking studies (fig. 5). 
The active binding pockets were identified by SiteMap. It calculates 
the binding site by an energetic grid based method. SiteMap 
identified five potential binding sites with site scores>0.9. The 
predicted active site, Site I had a site score of 1.081 and amino acids 
in this region were 115-119, 331, 335, 338, 339, 342, 343, 408, 409, 
412, 413, 422–42, 430-435, 477, 480, 481, 483, 484, 486. This site 
was used for further screening and docking studies. 
 
 
Fig. 5: Binding pocket 
 
Docking  
The modeled and refined protein was docked against FDA-approved 
drugs. Table 1 shows the compounds which had a high docking 
score. For the docking score, mainly four parameters were 
considered: (i) G-Score (ii) Glide energy (iii) H bonds and (iv) Good 
van-der-walls interactions. 
 
Table 1: Docking score of FDA approved drugs 
Compound Glide score  





Colistin  -10.673 
Abarelix  -10.446 





Fig. 6: Leuprolide Fig. 7: Triptorelin 
 
Higher the negative value of the docking score, better the binding affinity of the ligand and receptor. The minimum energy for binding and higher 
number of hydrogen bonds also indicates good binding affinity of ligands towards the receptor. The docking score of Leuprolide is-14.188. The 
complex (fig. 6) indicates that amino acids Tyr116, Tyr117, Leu431, Leu433, Asp480, Tyr481 and Gln 483 are involved in hydrogen bonding. 
Leuprolide forms seven hydrogen bonds with ACRBP/OY-TES-1. Triptorelin (fig. 7) forms hydrogen bonds (Tyr116, Phe404, Leu431, Leu433, 
Tyr481, Gln483) with a docking score of-13.512. The residues Tyr 116,Tyr 117,Ser 411, Ser 415, Tyr 434, Asp 478, Tyr 481, Gly483 are involved in 
hydrogen bonding with Naferelin (fig. 8).  
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Fig. 8: Naferelin Fig. 9: Goserelin 
 
DISCUSSION 
Acrosin binding protein (OY-TES-1) is normally expressed in 
developing and adult testis and anomalously expressed in a variety 
of tumor types, including lung, breast, and liver [9]. It is a member of 
a class of tumor-specific proteins that emerge as a consequence of 
tumor evolution. They do not drive the proliferation or survival, 
rather, they normalize the perturbed mitotic infrastructure 
responsible for disease-promoting genetic variation. In such context, 
if it is targeted, it is likely to represent therapeutic intervention 
targets with large therapeutic windows. It is also an important 
target due to its high expression in a variety of cancers and 
restricted expression in normal adult tissues, except for testis. The 
down-regulation of ACRBP/OY-TES-1 expression in mesenchymal 
stem cells caused cell growth inhibition, cell cycle arrest, and 
apoptosis induction and attenuation of migratory ability [27]. 
Luo et al. [11] had previously reported an over expression of 
ACRBP/OY-TES-1 in breast, epithelial ovarian, lung, liver colon and 
bladder cancer. Its mRNA levels have been detected in various 
cancers, including bladder, breast, lung, liver, and colon cancers 
while protein expression was reported in a majority of epithelial 
ovarian cancer. Thus, chemotherapeutic agents that bind to the 
protein can help to reduce levels of ACRBP/OY-TES-1 and induce cell 
death.  
The crystal structure of ACRBP/OY-TES-1 is not available in the 
Protein Data Bank so far. Hence we modeled the protein by using in 
silico methods and evaluated potential small molecules by docking 
them with the modeled protein structure. Analysis of the docked 
ligands showed that the glide score range was between − 14.188 
kcal/mol and-1 kcal/mol. Docked molecules showed intermolecular 
hydrogen bonding interactions between receptor-ligand molecules. 
The amino acids involved were hydrophobic (Leucine & 
Phenylalanine), polar (tyrosine) and charged amino acids (aspartic 
acid and glutamic acid). The binding modes and geometrical 
orientation of all compounds were almost identical, suggesting that 
all them occupied a common cavity in the receptor. The top four 
compounds were peptides and formed hydrogen bonds with Tyr. 
Hence we speculate that these compounds may successfully target 
and bind the ACRBP/OY-TES-1 molecule, We also hypothesize that 
these lead drug-like small molecules may serve as inhibitors of the 
ACRBP/OY-TES-1 protein in-vivo. 
Apart from being a promising target for chemotherapeutic 
intervention, ACRBP/OY-TES-1 expression in several cancers 
presents an opportunity for immunotherapeutic targeting. A cell-
mediated immunotherapy based approach not only ensures tumor 
elimination but also offers immune cell memory against any tumors 
that may develop in the future. Eliciting active immune surveillance 
may be difficult since the protein is intracellular and not membrane 
bound. Hence studying the mechanism of ACRBP/OY-TES-1 
turnover and its association with MHC Class I for presentation need 
to be studied. Identifying specific HLA Class I alleles that could 
present these turned over peptides may help engineer an immune 
intervention against tumors. One such an approach has been used 
for designing a fusion protein consisting of an IL-2 molecule linked 
to a soluble single chain TCR that recognizes an octapeptide (from 
p53 turnover) linked to HLA A*0201. This method may present a 
possible strategy to overcome the challenge of targeting intracellular 
proteins. Cell-mediated immunity may also be elicited with the help 
of dendritic cells, which are the most potent antigen presenting cells 
and can process and present antigens to both CD4 and CD8 T cells 
[28]. This approach may, as stated earlier, evince a memory 
response as well, virtually guaranteeing long term immune 
surveillance. But a dendritic cell vaccine route may not automatically 
translate to good clinical outcomes. The response to such vaccines as 
shown by clinical trials is far from encouraging and hence other 
approaches may need to be evaluated [29]. Apart from this, mimetic 
TCR like antibodies against peptide-MHC complexes which have 
been evaluated against several targets like MART-1, NY-ESO-1, HER2 
[30] etc. may also be used against ACRBP/OY-TES-1 expressing 
tumors. With the availability of numerous such approaches, it is 
possible to exploit the expression of the tumor associated protein for 
tailoring the best possible immunotherapeutic approach. 
CONCLUSION 
In this study, we computationally modeled the tertiary structure of 
the protein ACRB/OY-TES-1. Molecular docking was applied to 
explore the binding mechanism of ACRBP/OY-TES-1 with FDA-
approved drugs. Results indicate that peptides have a better binding 
affinity towards ACRBP/OY-TES-1. These potential drug candidates 
can further be validated in wet lab studies for their role as inhibitors 
of ACRBP/OY-TES-1. This protein that belongs to the CT family of 
antigens is frequently expressed in most cancers and can induce 
humoral immune response spontaneously in cancer patients, 
suggesting that it might be a promising immunotherapy target for 
different cancers as well. 
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